• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Carlyle Group Co-Founder And Co-Chairman David Rubenstein Joins Moderna's Board of Directors, Effective August 5, 2024 - Filing

    7/23/24 7:13:16 AM ET
    $CG
    $MRNA
    Investment Managers
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CG alert in real time by email

    Directors Robert Langer and Stephen Berenson will also retire from the Board.

    Get the next $CG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CG
    $MRNA

    CompanyDatePrice TargetRatingAnalyst
    The Carlyle Group Inc.
    $CG
    2/24/2026$67.00Outperform
    RBC Capital Mkts
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    The Carlyle Group Inc.
    $CG
    12/11/2025$74.00Buy
    UBS
    The Carlyle Group Inc.
    $CG
    10/3/2025$74.00Outperform
    BMO Capital Markets
    The Carlyle Group Inc.
    $CG
    7/10/2025$65.00Neutral → Buy
    Citigroup
    The Carlyle Group Inc.
    $CG
    5/14/2025$56.00Hold → Buy
    TD Cowen
    More analyst ratings

    $CG
    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Carlyle to Acquire Majority Stake in MAI Capital Management

    The new investment strengthens MAI's capital base, supports advisors, and provides continuity for clients and teams MAI Capital Management ("MAI"), a registered investment advisor ("RIA") focused on empowering clients to simplify, protect, and grow their wealth, today announced that it has signed an agreement for funds managed by global investment firm Carlyle (NASDAQ:CG) to acquire a majority stake in the company, valuing it at more than $2.8 billion. Carlyle initially invested in MAI in 2021 through its investment in Galway Holdings, which acquired MAI that year, and will become the majority owner upon closing, with Galway Holdings, funds managed by Harvest Partners, LP ("Harvest Partne

    3/31/26 7:30:00 AM ET
    $CG
    Investment Managers
    Finance

    Acentra Health Names New Senior Vice Presidents, Mohamed Karama and Nirav Dalal, to Drive Company Growth and Business Development

    MCLEAN, Va., March 25, 2026 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, announced today that Mohamed Karama has joined the company as Senior Vice President of Growth Acceleration and Performance, and Nirav Dalal has been promoted to Senior Vice President of Sales Leadership. These appointments advance Acentra Health's transformation initiatives and position the company for strategic growth. "As we continue transforming Acentra Health, we're investing in our growth engine," said Patty Obermaier, EVP, Chief Growth Offic

    3/25/26 9:33:00 AM ET
    $CG
    Investment Managers
    Finance

    SpendHound Reaches 1,000 Customers in only Two Years, Welcomes ZoomInfo as Enterprise Momentum Continues

    Rapid growth signals strong enterprise adoption and market momentum SpendHound, a subsidiary of YipitData and the #1 rated SaaS spend management platform on G2 that gives finance teams total visibility into software spend, today announced it has reached 1,000 customers in only two years, marking a major milestone in the company's breakout growth. The achievement is highlighted by the addition of ZoomInfo (NASDAQ:GTM), the leading go-to-market intelligence platform, as the company's 1,000th customer. "Reaching 1,000 customers is a huge milestone for our team and a clear signal of the trust the market has placed in us," said Vinicius Vacanti, Co-founder and CEO of YipitData. "Welcoming

    3/23/26 9:00:00 AM ET
    $CG
    $GTM
    Investment Managers
    Finance
    Computer Software: Prepackaged Software
    Technology

    $CG
    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Carlyle Group with a new price target

    RBC Capital Mkts initiated coverage of Carlyle Group with a rating of Outperform and set a new price target of $67.00

    2/24/26 7:47:48 AM ET
    $CG
    Investment Managers
    Finance

    Barclays resumed coverage on Moderna with a new price target

    Barclays resumed coverage of Moderna with a rating of Equal Weight and set a new price target of $25.00

    1/28/26 7:18:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Moderna with a new price target

    UBS resumed coverage of Moderna with a rating of Neutral and set a new price target of $34.00

    1/7/26 9:12:19 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CG
    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CG
    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CG
    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rubenstein David M.

    4 - Carlyle Group Inc. (0001527166) (Issuer)

    3/20/26 5:34:13 PM ET
    $CG
    Investment Managers
    Finance

    Large owner Carlyle Group Inc. sold $1,070,339,440 worth of shares (26,105,840 units at $41.00) and disposed of 2,113,483 shares (SEC Form 4)

    4 - Carlyle Group Inc. (0001527166) (Reporting)

    3/12/26 4:30:20 PM ET
    $CG
    Investment Managers
    Finance

    Large owner Carlyle Group Inc. converted options into 9,297,883 shares and disposed of 9,297,883 units of Class B Common Stock (SEC Form 4)

    4 - Carlyle Group Inc. (0001527166) (Reporting)

    3/6/26 7:02:25 PM ET
    $CG
    Investment Managers
    Finance

    $CG
    $MRNA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.

    SCHEDULE 13G/A - Moderna, Inc. (0001682852) (Subject)

    3/27/26 10:51:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by The Carlyle Group Inc.

    SCHEDULE 13G/A - Carlyle Group Inc. (0001527166) (Subject)

    3/26/26 4:44:46 PM ET
    $CG
    Investment Managers
    Finance

    SEC Form DEF 14A filed by Moderna Inc.

    DEF 14A - Moderna, Inc. (0001682852) (Filer)

    3/16/26 4:31:50 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CG
    $MRNA
    Leadership Updates

    Live Leadership Updates

    View All

    Acentra Health Names New Senior Vice Presidents, Mohamed Karama and Nirav Dalal, to Drive Company Growth and Business Development

    MCLEAN, Va., March 25, 2026 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, announced today that Mohamed Karama has joined the company as Senior Vice President of Growth Acceleration and Performance, and Nirav Dalal has been promoted to Senior Vice President of Sales Leadership. These appointments advance Acentra Health's transformation initiatives and position the company for strategic growth. "As we continue transforming Acentra Health, we're investing in our growth engine," said Patty Obermaier, EVP, Chief Growth Offic

    3/25/26 9:33:00 AM ET
    $CG
    Investment Managers
    Finance

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Carlyle to Host 2026 Shareholder Update

    WASHINGTON and NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Global investment firm Carlyle (NASDAQ:CG) announced today that it will host a Shareholder Update on Thursday, February 26, 2026. The Shareholder Update will include a series of presentations by the company's senior leadership team and will review Carlyle's growth outlook and financial objectives. Presentations will begin at 8:30 a.m. EST, followed by a Q&A session. Presentation materials and a live webcast will be posted on the day of the event and can be accessed on the Events & Presentations section of ir.carlyle.com. For those unable to join the live webcast, a replay will be available on the website following the event. Any

    2/2/26 8:01:00 AM ET
    $CG
    Investment Managers
    Finance

    $CG
    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

    SC 13D/A - Carlyle Group Inc. (0001527166) (Subject)

    11/15/24 5:22:29 PM ET
    $CG
    Investment Managers
    Finance

    Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

    SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)

    10/21/24 4:31:27 PM ET
    $CG
    Investment Managers
    Finance

    Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

    SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)

    10/15/24 4:31:27 PM ET
    $CG
    Investment Managers
    Finance

    $CG
    $MRNA
    Financials

    Live finance-specific insights

    View All

    Carlyle Presents Growth Outlook at 2026 Shareholder Update

    WASHINGTON and NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Global investment firm Carlyle (NASDAQ:CG) is announcing its growth outlook and financial objectives at the 2026 Shareholder Update, beginning today at 8:30 a.m. EST. The program will include presentations by senior leadership, followed by a Q&A session. Carlyle will announce three-year financial targets to be achieved by the end of 2028, including: FRE of $1.9+ billionInflows of $200+ billionDE per common share of $6.00+ Carlyle is also announcing that its Board of Directors has approved a new $2 billion share repurchase authorization. The authorization provides the firm with flexibility to repurchase shares as part of its disc

    2/26/26 7:01:00 AM ET
    $CG
    Investment Managers
    Finance

    Carlyle Secured Lending, Inc. Announces Financial Results For Fourth Quarter and Full Year Ended December 31, 2025, Declares First Quarter 2026 Dividend of $0.40 Per Common Share

    NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, "we," "us," "our," "CGBD" or the "Company") (NASDAQ:CGBD) today announced its financial results for its fourth quarter and full year ended December 31, 2025. Alex Chi, CGBD's Chief Executive Officer, said, "As CGBD's newly appointed CEO, I look forward to continuing to build on Carlyle's strong track record and world-class platform. Building off record origination volume in the fourth quarter and full year 2025, we continue to expand our origination apparatus and are focused on further harnessing the full power of the OneCarlyle platform. The depth of our underwriting se

    2/24/26 4:05:00 PM ET
    $CG
    $CGBD
    Investment Managers
    Finance
    Finance: Consumer Services

    Carlyle Secured Lending, Inc. Schedules Earnings Release and Quarterly Earnings Call to Discuss its Financial Results for the Fourth Quarter and Full Year Ended December 31, 2025

    NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. ("Carlyle Secured Lending") (NASDAQ:CGBD) will host a conference call at 11:00 a.m. (Eastern Time) on Wednesday, February 25, 2026 to announce its financial results for the fourth quarter and full year ended December 31, 2025. The Company will report its quarterly financial results on Tuesday, February 24, 2026. The conference call will be available via public webcast via a link on Carlyle Secured Lending's website at carlylesecuredlending.com and will also be available on the website soon after the call's completion. About Carlyle Secured Lending, Inc.     Carlyle Secured Lending, Inc. is a publicly traded (NASDA

    1/27/26 4:05:00 PM ET
    $CG
    $CGBD
    Investment Managers
    Finance
    Finance: Consumer Services